TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA

Hodgkin lymphoma (HL) represents one of the great success stories in hematology going from a uniformly fatal disease; to one that is curable in the vast majority of cases. Despite this success; approximately 5–10 % HL patients are refractory to initial treatment and 10–30 % of patients will relapse...

Full description

Saved in:

Bibliographic Details
Published in:	Onkogematologii͡a Vol. 12; no. 2; pp. 8 - 13
Main Author:	Baryakh, E. A.
Format:	Journal Article
Language:	English
Published:	ABV-press 01-06-2017
Subjects:	autologous hematopoietic cell transplantation brentuximab vedotin cd30 hodgkin lymphoma refractory disease relapse
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Hodgkin lymphoma (HL) represents one of the great success stories in hematology going from a uniformly fatal disease; to one that is curable in the vast majority of cases. Despite this success; approximately 5–10 % HL patients are refractory to initial treatment and 10–30 % of patients will relapse after achieving an initial complete remission. The standard treatment is second-line therapy followed by autologous hematopoietic stem cell transplantation (autoHSCT); which cures an additional 50 % of patients. Brentuximab Vedotin; “antibody-drug conjugate”; dramatically changed the possibilities of therapy for relapses/refractory HL. The article presents a review of the literature on the treatment of relapses/refractory HL.
ISSN:	1818-8346 2413-4023
DOI:	10.17650/1818-8346-2017-12-2-8-13